ArticleJournal of nutritional science2026
Gluten contamination in commercially available gluten-free products in Jordan: a cross-sectional market surveillance study with public health implications.
Article in Journal of nutritional science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This cross-sectional based market surveillance study examined the level of gluten contamination in commercially manufactured products labelled 'gluten-free' in Jordan and compared the results to the globally recognised 20 mg/kg gluten safety limit for people with coeliac disease and other gluten-related disorders. From August 2022 to November 2024, 182 goods from 25 different food categories were tested in retail locations in Jordan's main governorates. A validated monoclonal-based antibody-sandwich ELISA was used to determine the levels of gluten concentration, and a 95% CI was used to describe the prevalence of contamination. Overall, 47 of 182 products (25.8%; 95% CI: 19.7-32.6%) exceeded 20 mg/kg gluten. With maximum concentrations of 395.8 mg/kg, the highest non-compliance was found in rice-based goods (66.7%), milk products (50.0), and cookies (42.9). On the other hand, with the fact that several categories had rather small sample sizes, no violations were found in any of them. Jordan had a higher rate of contamination than a number of other places, including Europe (0.5%), India (10.8% of packaged items marketed as gluten-free), and Mexico (17.4%). The findings highlight clinically relevant issues with the quality of gluten-free products and support further monitoring, manufacturing supervision, and regulatory actions to better protect customers who depend on strict gluten avoidance guidelines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.